ClinicalTrials.gg
CompletedNCT02630706Updated Dec 7, 2018Results posted

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
5th of 28
506 · median 83
Started
2015
the only one that year
Phase 3
11 of 28
none open now
Registered
17th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 17th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.

Read the detailed description

This study includes a 1-week screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off and/or metformin dose stable period (as necessary), a 2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asian participants ≥18 years of age at the time of initial Screening.
  • Type 2 diabetes mellitus as per American Diabetes Association guidelines.
  • Metformin monotherapy (≥1500 mg/day) with an initial Screening of 7.0-10.5% (53-91 mmol/mol) OR metformin monotherapy (\<1500 mg/day) with an initial Screening A1C of 7.5-11.0% (58-97 mmol/mol) OR dual combination therapy with metformin + sulfonylurea, dipeptidyl peptidase-4 (DDP-4) inhibitor, meglitinide, or alpha-glucosidase inhibitor with an initial Screening A1C of 6.5-9.5% (48-80 mmol/mol).
  • (BMI) ≥18.0 kg/m\^2.
  • Male or female not of .
  • Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of .

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis.
  • History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant.)
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study start.
  • Mean value for triplicate screening sitting systolic blood pressure >160 mm Hg and/or diastolic blood pressure >90 mm Hg after at least a 5-minute seated rest at screening
  • Active, obstructive uropathy or indwelling urinary catheter.
  • History of ≤5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking.
  • Any malabsorption condition.
  • Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start.
  • Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable prior to study start.
  • A known or intolerance to any sodium glucose co-transporter (SGLT2) inhibitor.
  • On a previous clinical study with ertugliflozin.
  • Is taking blood pressure or lipid altering medications that have not been on a stable dose for at least 4 weeks prior to study start.
  • Current treatment for hyperthyroidism.
  • Male participants with a serum creatinine >=1.3 mg/dL (>=115 mol/L) or female participants with a serum creatinine >=1.2 mg/dL (>=106 mol/L) or participants with an estimated (eGFR) \<55 mL/min/1.73m\^2 according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation at screening.
  • An (AST) or alanine transaminase (ALT) >2X the (ULN) range at screening, or a total >1.5 X the ULN unless the participant has a history of Gilbert's.
  • On thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to study start.
  • A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease.
  • Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), another SGLT2 inhibitor, bromocriptine, colesevelam, rosiglitazone or pioglitazone, or any other AHA with the exception of the protocol-approved agents.
  • Is on or likely to require treatment ≥14 consecutive days or repeated courses of pharmacologic doses of .
  • Has undergone a surgical procedure within 6 weeks prior to study start or has planned major surgery during the study.
  • Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication.
  • Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication.
  • Donated blood or blood products within 6 weeks of study start.
  • Has (HIV).
  • Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells.
  • Has clinically important hematological disorders (such as aplastic anemia, myeloproliferative or myelodyplastic syndromes, thrombocytopenia.)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.

    Drug: Ertugliflozin 5 mg · Drug: Placebo matching ertugliflozin · Drug: Metformin · Drug: Glimepiride

  • Experimental
    Ertugliflozin 15 mg

    Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.

    Drug: Ertugliflozin 15 mg · Drug: Metformin · Drug: Glimepiride

  • Placebo comparator
    Placebo

    Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.

    Drug: Placebo matching ertugliflozin · Drug: Metformin · Drug: Glimepiride

Interventions

  • Ertugliflozin 5 mg oral tablet taken once daily

    Also known as: MK-8835, PF-04971729

  • Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily

    Also known as: MK-8835, PF-04971729

  • DrugPlacebo matching ertugliflozin

    Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily

  • Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

  • Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  3. Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 28 weeks

  4. Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 28 weeks

  5. Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 26 weeks

  6. Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 26 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  3. Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

    The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  4. Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)

    The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  5. Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  6. Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  7. Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

    This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  8. Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

    This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  9. Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

    This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  10. Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

    This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  11. Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  12. Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  13. Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

    Time frame: Week 26

  14. Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

    Time frame: Week 26

  15. Time to Glycemic Rescue Therapy

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

    Time frame: Up to 183 days

  16. Time to Glycemic Rescue Therapy (China Subpopulation)

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

    Time frame: Up to 149 days

  17. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 6: Pre-Dose

  18. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 12: Pre-Dose

  19. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 12: 60 min. Post-Dose

  20. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 18: Pre-Dose

  21. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 18: 60 min. Post-Dose

  22. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 26: Pre-Dose

  23. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 6: Pre-Dose

  24. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 12: Pre-Dose

  25. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 12: 60 min. Post-Dose

  26. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 18: Pre-Dose

  27. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 18: 60 min. Post-Dose

  28. Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

    No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

    Time frame: Week 26: Pre-Dose

07

Results

Posted Dec 7, 2018

Participant flow

In total, 1078 participants were screened, and 506 participants were randomized at 50 sites in China, Hong Kong, Republic of Korea, the Philippines, and Taiwan.

Participant flow — Overall Study
MilestoneErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Started170169167
Treated170169167
Completed163160157
Not completed7910
Withdrew: Adverse event211
Withdrew: Lost to follow-up012
Withdrew: Physician decision110
Withdrew: Pregnancy010
Withdrew: Withdrawal by subject457

Outcome measures

PrimaryChange From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage A1C
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)
Percentage A1CErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)-1.00 (-1.12 to -0.88)-0.89 (-1.01 to -0.77)-0.20 (-0.33 to -0.08)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 (cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), country (China, other), baseline eGFR (continuous) and the interaction of time by treatment.) · Difference in the lsm vs. placebo: -0.69 · 95% CI -0.85 to -0.52Least squares means = LSM
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -0.80 · 95% CI -0.97 to -0.63
PrimaryChange From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage A1C
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)
Percentage A1CErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)-1.01 (-1.14 to -0.87)-0.92 (-1.05 to -0.79)-0.24 (-0.38 to -0.10)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 (cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment.) · Difference in the lsm vs. placebo: -0.68 · 95% CI -0.86 to -0.50
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -0.76 · 95% CI -0.95 to -0.58
PrimaryPercentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 28 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)56.553.359.3
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Difference in % vs. placebo: -6.0 · 95% CI -16.5 to 4.6
  • Ertugliflozin 5 mg vs Placebo · Difference in % vs. placebo: -2.8 · 95% CI -13.3 to 7.7
PrimaryPercentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 28 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)54.450.459.3
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Difference in % vs. placebo: -8.9 · 95% CI -20.5 to 3.0
  • Ertugliflozin 5 mg vs Placebo · Difference in % vs. placebo: -4.8 · 95% CI -16.5 to 6.9
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 26 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)1.20.61.8
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 26 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)0.70.72.2
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)-37.09 (-41.73 to -32.45)-34.47 (-39.15 to -29.79)-6.69 (-11.57 to -1.82)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -27.78 · 95% CI -33.85 to -21.70
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -30.40 · 95% CI -36.45 to -24.35
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)-39.01 (-43.87 to -34.15)-36.67 (-41.64 to -31.71)-10.46 (-15.61 to -5.31)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -26.21 · 95% CI -32.41 to -20.01
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -28.55 · 95% CI -34.67 to -22.43
SecondaryChange From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)-2.95 (-3.29 to -2.60)-3.18 (-3.52 to -2.83)-1.17 (-1.54 to -0.81)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -2.00 · 95% CI -2.51 to -1.50
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -1.78 · 95% CI -2.28 to -1.28
SecondaryChange From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)-3.11 (-3.50 to -2.72)-3.38 (-3.78 to -2.98)-1.33 (-1.75 to -0.91)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in ls means vs. placebo: -2.05 · 95% CI -2.63 to -1.21
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -1.79 · 95% CI -2.36 to -1.21
SecondaryPercentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)38.240.816.2
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Logistic regression model · p = <0.001 · Adjusted odds ratio relative to placebo: 4.56 · 95% CI 2.49 to 8.35
  • Ertugliflozin 5 mg vs Placebo · Logistic regression model · p = <0.001 · Adjusted odds ratio relative to placebo: 4.59 · 95% CI 2.52 to 8.36
SecondaryPercentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)35.342.218.5
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Logistic regression model · p = <0.001 · Adjusted odds ratio relative to placebo: 4.49 · 95% CI 2.32 to 8.68
  • Ertugliflozin 5 mg vs Placebo · Logistic regression model · p = <0.001 · Adjusted odds ratio relative to placebo: 3.47 · 95% CI 1.77 to 6.80
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)-5.09 (-6.78 to -3.40)-3.87 (-5.58 to -2.16)0.22 (-1.58 to 2.01)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -4.09 · 95% CI -6.48 to -1.69
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = <0.001 · Difference in the ls means vs. placebo: -5.30 · 95% CI -7.68 to -2.92
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)-5.64 (-7.53 to -3.75)-4.19 (-6.14 to -2.25)-1.56 (-3.61 to 0.49)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = 0.058 · Difference in the ls means vs. placebo: -2.64 · 95% CI -5.36 to 0.09
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = 0.003 · Difference in the ls means vs. placebo: -4.08 · 95% CI -6.78 to -1.39
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)-2.38 (-3.51 to -1.25)-2.36 (-3.50 to -1.22)-0.96 (-2.16 to 0.24)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = 0.086 · Difference in the ls means vs. placebo: -1.40 · 95% CI -3.00 to 0.20
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = 0.081 · Difference in the ls means vs. placebo: -1.42 · 95% CI -3.01 to 0.17
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)-2.82 (-4.11 to -1.54)-2.77 (-4.09 to -1.45)-1.82 (-3.21 to -0.43)
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · cLDA · p = 0.315 · Difference in the ls means vs. placebo: -0.95 · 95% CI -2.80 to 0.90
  • Ertugliflozin 5 mg vs Placebo · cLDA · p = 0.282 · Difference in the ls means vs. placebo: -1.00 · 95% CI -2.83 to 0.83
SecondaryPercentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)14.715.42.4
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Logistic regression model · p = 0.001 (Nominal p-values were provided.) · Adjusted odds ratio relative to placebo: 8.90 · 95% CI 2.46 to 32.22
  • Ertugliflozin 5 mg · Logistic regression model · p = <0.001 (Nominal p-values were provided.) · Adjusted odds ratio relative to placebo: 10.69 · 95% CI 2.95 to 38.71
SecondaryPercentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)14.717.03.0
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Logistic regression model · p = <0.001 (Nominal p-values were provided.) · Adjusted odds ratio relative to placebo: 8.34 · 95% CI 2.52 to 27.60
  • Ertugliflozin 5 mg · Logistic regression model · p = <0.001 (Nominal p-values were provided.) · Adjusted odds ratio relative to placebo: 8.29 · 95% CI 2.44 to 28.11
SecondaryPercentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.1.20.69.6
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in % (ert. 15 mg. - placebo): -9.0 · 95% CI -14.5 to -5.0Miettinen \& Nurminen method stratified by country ('China' or 'other') for the overall population.
  • Ertugliflozin 5 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in % (ert. 5 mg. - placebo): -8.4 · 95% CI -14.0 to -4.4Miettinen \& Nurminen method stratified by country ('China' or 'other') for the overall population.
SecondaryPercentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)
Percentage of ParticipantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)0.00.79.6
Statistical analysis
  • Ertugliflozin 15 mg vs Placebo · Miettinen & Nurminen method · p = 0.001 · Difference in % (ert. 15 mg. - placebo): -8.9 · 95% CI -15.1 to -4.2
  • Ertugliflozin 5 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in % (ert. 5 mg. - placebo): -9.6 · 95% CI -15.8 to -5.7
SecondaryTime to Glycemic Rescue Therapy

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

Time frame:
Up to 183 days
Reported as:
Median · Days
Time to Glycemic Rescue Therapy
DaysErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Time to Glycemic Rescue TherapyNA (41 to 85)NA (149 to 149)NA (22 to 183)
SecondaryTime to Glycemic Rescue Therapy (China Subpopulation)

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.

Time frame:
Up to 149 days
Reported as:
Median · Days
Time to Glycemic Rescue Therapy (China Subpopulation)
DaysErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Time to Glycemic Rescue Therapy (China Subpopulation)—NA (149 to 149)NA (22 to 145)
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 6: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach9.17 ± 18.3924.59 ± 43.84—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 12: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach8.18 ± 15.2527.11 ± 66.02—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 12: 60 min. Post-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach91.49 ± 50.61277.60 ± 130.66—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 18: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach6.59 ± 12.5317.54 ± 24.62—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 18: 60 min. Post-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach91.40 ± 44.77274.23 ± 146.14—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 26: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach7.34 ± 14.1826.66 ± 62.17—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 6: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)7.88 ± 14.8822.29 ± 42.81—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 12: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)7.40 ± 12.2123.84 ± 52.64—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 12: 60 min. Post-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)97.36 ± 48.98294.49 ± 124.73—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 18: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)6.30 ± 11.5017.07 ± 27.06—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 18: 60 min. Post-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)94.82 ± 41.40285.28 ± 141.59—
SecondaryErtugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)

No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.

Time frame:
Week 26: Pre-Dose
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
ng/mLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)7.26 ± 14.0924.91 ± 57.95—

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg0/170 (0%)9/170 (5.3%)22/170 (12.9%)
Ertugliflozin 15 mg0/169 (0%)10/169 (5.9%)31/169 (18.3%)
Placebo0/167 (0%)2/167 (1.2%)44/167 (26.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/1700/1691/167
Cubital tunnel syndromeNervous system disorders0/1700/1691/167
Microvascular coronary artery diseaseCardiac disorders0/1701/1690/167
Vertigo positionalEar and labyrinth disorders0/1701/1690/167
Dacryostenosis acquiredEye disorders0/1701/1690/167
PneumoniaInfections and infestations0/1701/1690/167
Blood glucose increasedInvestigations0/1701/1690/167
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1701/1690/167
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1701/1690/167
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1701/1690/167
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
HyperuricaemiaMetabolism and nutrition disorders5/1709/16920/167
Upper respiratory tract infectionInfections and infestations4/1709/16914/167
NasopharyngitisInfections and infestations9/1709/16911/167
HypoglycaemiaMetabolism and nutrition disorders6/1709/1692/167

Baseline characteristics

The analysis population included all randomized participants who received at least one dose of investigational product.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean56.1 ± 9.056.3 ± 9.356.9 ± 9.056.5 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Female757179225
Male959888281
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
American Indian or Alaska Native0000
Asian170169167506
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Body Weight
Body Weight(Kilograms)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean71.4 ± 11.169.5 ± 10.970.1 ± 12.470.3 ± 11.5
Baseline Hemoglobin A1C (A1C)
Baseline Hemoglobin A1C (A1C)(Percentage A1C)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean8.14 ± 0.898.09 ± 0.918.13 ± 0.968.12 ± 0.92
Baseline Fasting Plasma Glucose (FPG)
Baseline Fasting Plasma Glucose (FPG)(mg/dL)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean170.1 ± 36.0167.3 ± 41.1165.8 ± 37.6167.8 ± 38.3
Baseline estimated glomerular filtration rate (eGFR)
Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m^2)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
Mean97.9 ± 19.2100.2 ± 19.899.9 ± 20.299.3 ± 19.7
Country
Country(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgPlaceboTotal
China136135135406
Hong Kong1010727
Korea, Republic of1310932
Philippines78823
Taiwan46818

8 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Xu H, O'Gorman MT, Nepal S, James LP, Ginman K, Pithavala YK. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1395-1404. doi: 10.1002/cpdd.1000. Epub 2021 Jul 20. PubMed 34288547 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, Yan P, Pan S, Lauring B, Liu S, Huyck S, Qiu Y, Terra SG. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019 Jun;21(6):1474-1482. doi: 10.1111/dom.13681. Epub 2019 Apr 5. PubMed 30830724 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in Dec 2018, 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 15, 2015
StartActual
Dec 16, 2015
Primary completionActual
Dec 27, 2017
CompletionActual
Dec 27, 2017
Results first posted
Dec 7, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02630706
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 15, 2015
Start date
Dec 16, 2015
Primary completion
Dec 27, 2017
Completion
Dec 27, 2017
Results posted
Dec 7, 2018
Last update
Dec 7, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion